{"id":"colistin-polymyxin-b-tigecycline-eravacycline","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL1089240","moleculeType":"Small molecule","molecularWeight":"1155.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Colistin and polymyxin B are polymyxin antibiotics that bind to and disrupt the outer membrane of gram-negative bacteria, causing cell lysis. Tigecycline and eravacycline are tetracycline-class antibiotics that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. The combination exploits different mechanisms to overcome resistance and achieve enhanced bactericidal activity against extensively drug-resistant pathogens.","oneSentence":"This combination uses colistin/polymyxin B to disrupt bacterial cell membranes while tigecycline/eravacycline inhibits protein synthesis, providing synergistic activity against multidrug-resistant gram-negative bacteria.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:30:26.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant gram-negative bacterial infections"},{"name":"Extensively drug-resistant Acinetobacter baumannii infections"},{"name":"Carbapenem-resistant Enterobacteriaceae infections"}]},"trialDetails":[{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Colistin/Polymyxin B + Tigecycline/Eravacycline","genericName":"Colistin/Polymyxin B + Tigecycline/Eravacycline","companyName":"National University of Singapore","companyId":"national-university-of-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses colistin/polymyxin B to disrupt bacterial cell membranes while tigecycline/eravacycline inhibits protein synthesis, providing synergistic activity against multidrug-resistant gram-negative bacteria. Used for Multidrug-resistant gram-negative bacterial infections, Extensively drug-resistant Acinetobacter baumannii infections, Carbapenem-resistant Enterobacteriaceae infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}